FolioMetrix’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

FolioMetrix’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$287K	Buy	16,000 +4,000	+33%	+$122K	0.12%	156
2015 Q1	$312K	Hold	12,000	–	–	0.16%	113
2014 Q4	$157K	Buy	+12,000	New	+$150K	0.11%	155

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

FolioMetrix's HZNP Position: Q2 2015 in Review

FolioMetrix increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 33% in Q2 2015, buying an estimated $122K and bringing the position to 16,000 shares worth $287K. The position accounts for 0.12% of the portfolio, ranked #156.

FolioMetrix first reported a position in HZNP in Q4 2014 and has held it in 3 quarters since. The position peaked at $312K in Q1 2015. 213 funds tracked by Wall St. Rank hold HZNP as of Q2 2015.

FolioMetrix held 16,000 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $287K as of Q2 2015.
FolioMetrix bought 4,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2015, an estimated $122K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.12% of FolioMetrix's portfolio in Q2 2015, its #156 holding.
FolioMetrix first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and has held it in 3 quarters since.
FolioMetrix's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $312K in Q1 2015.
213 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2015.

Based on FolioMetrix's 13F filing for Q2 2015, filed 5 Aug 2015.